Current vaccine trials in glioblastoma: A review

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Xu, Linda W ^a   Chow, Kevin K H ^a   Lim, Michael ^b   Li, Gordon ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 2; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; RECOMBINANT GAMMA INTERFERON; RESIQUIMOD; TEMOZOLOMIDE; VITESPEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADJUVANT CHEMOTHERAPY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; EPSTEIN BARR VIRUS; GLIOBLASTOMA; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC MELANOMA; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; BRAIN NEOPLASMS; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; TRANSPLANTATION; TUMOR EMBOLISM;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS;

EID: 84899556879     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/796856     Document Type: Review

References (68)

1. Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330
2. Stupp R., Hegi M. E., Mason W. P., van den Bent M. J., Taphoorn M. J., Janzer R. C., Ludwin S. K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. A., Gijtenbeek J., Marosi C., Vecht C. J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J. G., Mirimanoff R.-O., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology 2009 10 5 459 466 2-s2.0-65349121788 10.1016/S1470-2045(09)70025-7
3. Johnson D. R., O'Neill B. P., Glioblastoma survival in the United States before and during the temozolomide era. Journal of Neuro-Oncology 2012 107 359 364 2-s2.0-80054967330 10.1007/s11060-011-0749-4
4. Atkins M. B., Kunkel L., Sznol M., Rosenberg S. A., High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer Journal from Scientific American 2000 6 1, supplement S11 S14 2-s2.0-0033848628
5. Agarwala S. S., Kirkwood J. M., Adjuvant interferon treatment for melanoma. Hematology/Oncology Clinics of North America 1998 12 4 823 833 2-s2.0-0031660952 10.1016/S0889-8588(05)70025-3
6. Disis M. L., Wallace D. R., Gooley T. A., Dang Y., Slota M., Lu H., Coveler A. L., Childs J. S., Higgins D. M., Fintak P. A., Dela Rosa C., Tietje K., Link J., Waisman J., Salazar L. G., Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Journal of Clinical Oncology 2009 27 28 4685 4692 2-s2.0-70350435441 10.1200/JCO.2008.20.6789
7. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001 344 11 783 792 2-s2.0-0035869407 10.1056/NEJM200103153441101
8. Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E. Jr., Davidson N. E., Tan-Chiu E., Martino S., Paik S., Kaufman P. A., Swain S. M., Pisansky T. M., Fehrenbacher L., Kutteh L. A., Vogel V. G., Visscher D. W., Yothers G., Jenkins R. B., Brown A. M., Dakhil S. R., Mamounas E. P., Lingle W. L., Klein P. M., Ingle J. N., Wolmark N., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 2005 353 16 1673 1684 2-s2.0-26844536978 10.1056/NEJMoa052122
9. Chow K. K., Gottschalk S., Cellular immunotherapy for high-grade glioma. Immunotherapy 2011 3 3 423 434 2-s2.0-79952665097 10.2217/imt.10.110
10. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 2010 363 5 411 422 2-s2.0-77955066199 10.1056/NEJMoa1001294
11. Hynes N. E., Lane H. A., ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 2005 5 5 341 354 2-s2.0-18344390418 10.1038/nrc1609
12. Humphrey P. A., Wong A. J., Vogelstein B., Zalutsky M. R., Fuller G. N., Archer G. E., Friedman H. S., Kwatra M. M., Bigner S. H., Bigner D. D., Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 1990 87 11 4207 4211 2-s2.0-0025313141 10.1073/pnas.87.11.4207
13. Wong A. J., Ruppert J. M., Bigner S. H., Grzeschik C. H., Humphrey P. A., Bigner D. S., Vogelstein B., Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America 1992 89 7 2965 2969 2-s2.0-0026548240
14. Antonyak M. A., Moscatello D. K., Wong A. J., Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. Journal of Biological Chemistry 1998 273 5 2817 2822 2-s2.0-0032579405 10.1074/jbc.273.5.2817
15. Moscatello D. K., Holgado-Madruga M., Emlet D. R., Montgomery R. B., Wong A. J., Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. Journal of Biological Chemistry 1998 273 1 200 206 2-s2.0-0031961980 10.1074/jbc.273.1.200
16. Archer G., Bigner D., Friedman A., Dendritic cell vaccine for intracranial tumors 1 (DC VICTORI Trial). Proceedings of the Society of Neuro-Oncology Meeting 2004
17. Sampson J. H., Archer G. E., Mitchell D. A., Heimberger A. B., Herndon J. E. II, Lally-Goss D., McGehee-Norman S., Paolino A., Reardon D. A., Friedman A. H., Friedman H. S., Bigner D. D., An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics 2009 8 10 2773 2779 2-s2.0-70350236627 10.1158/1535-7163.MCT-09-0124
18. Sampson J. H., Archer G. E., Mitchell D. A., Heimberger A. B., Bigner D. D., Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology 2008 20 5 267 275 2-s2.0-51349083585 10.1016/j.smim.2008.04.001
19. Lai R. K., Recht L. D., Reardon D. A., Long-term follow-up of ACT III: a phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Proceedings of the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors 2011 34 40
20. Heimberger A. B., Hussain S. F., Aldape K., Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. Journal of Clinical Oncology 2006 24
21. Sampson J. H., Aldape K. D., Archer G. E., Coan A., Desjardins A., Friedman A. H., Friedman H. S., Gilbert M. R., Herndon J. E., McLendon R. E., Mitchell D. A., Reardon D. A., Sawaya R., Schmittling R., Shi W., Vredenburgh J. J., Bigner D. D., Heimberger A. B., Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology 2011 13 3 324 333 2-s2.0-79955784386 10.1093/neuonc/noq157
22. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology 2005 23 10 2346 2357 2-s2.0-20244366111 10.1200/JCO.2005.00.240
23. Cui Y., Zhang H., Meadors J., Poon R., Guimond M., Mackall C. L., Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009 114 18 3831 3840 2-s2.0-70449726875 10.1182/blood-2009-03-212134
24. Louis C. U., Straath K., Bollard C. M., Gerken C., Huls M. H., Gresik M. V., Wu M.-F., Weiss H. L., Gee A. P., Brenner M. K., Rooney C. M., Heslop H. E., Gottschalk S., Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009 113 11 2442 2450 2-s2.0-63849262293 10.1182/blood-2008-05- 157222
25. Li G., Mitra S. S., Monje M., Henrich K. N., Bangs C. D., Nitta R. T., Wong A. J., Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. Journal of Neuro-Oncology 2012 108 395 402 2-s2.0-84857491279 10.1007/s11060-012-0842-3
26. Liau L. M., Black K. L., Martin N. A., Sykes S. N., Bronstein J. M., Jouben-Steele L., Mischel P. S., Belldegrun A., Cloughesy T. F., Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Neurosurgical Focus 2000 9 6, article e8 2-s2.0-0142089462
27. Liau L. M., Prins R. M., Kiertscher S. M., Odesa S. K., Kremen T. J., Giovannone A. J., Lin J.-W., Chute D. J., Mischet P. S., Cloughesy T. F., Roth M. D., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research 2005 11 15 5515 5525 2-s2.0-23044479028 10.1158/1078-0432.CCR-05-0464
28. Freije W. A., Castro-Vargas F. E., Fang Z., Horvath S., Cloughesy T., Liau L. M., Mischel P. S., Nelson S. F., Gene expression profiling of gliomas strongly predicts survival. Cancer Research 2004 64 18 6503 6510 2-s2.0-4644313275 10.1158/0008-5472.CAN-04-0452
29. Lee Y., Scheck A. C., Cloughesy T. F., Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Medical Genomics 2008 1, article 52
30. Phillips H. S., Kharbanda S., Chen R., Forrest W. F., Soriano R. H., Wu T. D., Misra A., Nigro J. M., Colman H., Soroceanu L., Williams P. M., Modrusan Z., Feuerstein B. G., Aldape K., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006 9 3 157 173 2-s2.0-33644820339 10.1016/j.ccr.2006.02.019
31. Prins R. M., Soto H., Konkankit V., Odesa S. K., Eskin A., Yong W. H., Nelson S. F., Liau L. M., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research 2011 17 6 1603 1615 2-s2.0-79952711945 10.1158/1078-0432.CCR-10-2563
32. Lasky J. L., Panosyan E. H., Plant A., Davidson T., Yong W. H., Prins R. M., Liau L. M., Moore T. B., Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Research 2013 33 2047 2056
33. Tomai M. A., Miller R. L., Lipson K. E., Kieper W. C., Zarraga I. E., Vasilakos J. P., Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Review of Vaccines 2007 6 5 835 847 2-s2.0-35348990231 10.1586/14760584.6.5.835
34. Zhu X., Fallert-Junecko B. A., Fujita M., Ueda R., Kohanbash G., Kastenhuber E. R., McDonald H. A., Liu Y., Kalinski P., Reinhart T. A., Salazar A. M., Okada H., Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN- α and IFN- γ dependent manners. Cancer Immunology, Immunotherapy 2010 59 9 1401 1409 2-s2.0-77955515616 10.1007/s00262-010-0876-3
35. Fadul C. E., Fisher J. L., Hampton T. H., Lallana E. C., Li Z., Gui J., Szczepiorkowski Z. M., Tosteson T. D., Rhodes C. H., Wishart H. A., Lewis L. D., Ernstoff M. S., Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. Journal of Immunotherapy 2011 34 4 382 389 2-s2.0-79955591522 10.1097/CJI.0b013e318215e300
36. Dutoit V., Herold-Mende C., Hilf N., Schoor O., Beckhove P., Bucher J., Dorsch K., Flohr S., Fritsche J., Lewandrowski P., Lohr J., Rammensee H.-G., Stevanovic S., Trautwein C., Vass V., Walter S., Walker P. R., Weinschenk T., Singh-Jasuja H., Dietrich P.-Y., Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012 135 4 1042 1054 2-s2.0-84860209098 10.1093/brain/aws042
37. James A., Mulholland P., Peoples S., Updated results from a Cancer Research UK first in man Phase I trial of IMA950 (a novel multi peptide vaccine) plus GM-CSF in patients with newly diagnosed glioblastoma. Vienna, Austria
38. Singh S. K., Clarke I. D., Terasaki M., Bonn V. E., Hawkins C., Squire J., Dirks P. B., Identification of a cancer stem cell in human brain tumors. Cancer Research 2003 63 18 5821 5828 2-s2.0-0141842674
39. Yuan X., Curtin J., Xiong Y., Liu G., Waschsmann-Hogiu S., Farkas D. L., Black K. L., Yu J. S., Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004 23 58 9392 9400 2-s2.0-11244293572 10.1038/sj.onc.1208311
40. Jian G. Z., Eguchi J., Kruse C. A., Gomez G. G., Fakhrai H., Schroter S., Ma W., Hoa N., Minev B., Delgado C., Wepsic H. T., Okada H., Jadus M. R., Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clinical Cancer Research 2007 13 2 566 575 2-s2.0-33846886376 10.1158/1078-0432.CCR-06-1576
41. Saikali S., Avril T., Collet B., Hamlat A., Bansard J.-Y., Drenou B., Guegan Y., Quillien V., Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R α 2, gp100 and TRP-2 for immunotherapy. Journal of Neuro-Oncology 2007 81 2 139 148 2-s2.0-33845698912 10.1007/s11060-006-9220-3
42. Liu G., Ying H., Zeng G., Wheeler C. J., Black K. L., Yu J. S., HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Research 2004 64 14 4980 4986 2-s2.0-3142710121 10.1158/0008-5472.CAN-03-3504
43. Liu G., Khong H. T., Wheeler C. J., Yu J. S., Black K. L., Ying H., Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. Journal of Immunotherapy 2003 26 4 301 312 2-s2.0-0038167151 10.1097/00002371-200307000- 00002
44. Liu G., Yu J. S., Zeng G., Yin D., Xie D., Black K. L., Ying H., AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. Journal of Immunotherapy 2004 27 3 220 226 2-s2.0-4344706290
45. Okano F., Storkus W. J., Chambers W. H., Pollack I. F., Okada H., Identification of a novel HLA-A0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clinical Cancer Research 2002 8 2851 2855
46. Tamura K., Aoyagi M., Wakimoto H., Ando N., Nariai T., Yamamoto M., Ohno K., Accumulation of CD133-positive glioma cells after high-dose irradiation by gamma knife surgery plus external beam radiation: Clinical article. Journal of Neurosurgery 2010 113 2 310 318 2-s2.0-77953276147 10.3171/2010.2.JNS091607
47. + cancer stem cells in glioblastoma. Molecular Cancer 2006 5, article 67 2-s2.0-33845671339 10.1186/1476-4598-5-67
48. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B. M., Becker N., Lichter P., Unterberg A., Radlwimmer B., Herold-Mende C. C., Stem cell marker CD133 affects clinical outcome in glioma patients. Clinical Cancer Research 2008 14 1 123 129 2-s2.0-40749155451 10.1158/1078-0432.CCR-07-0932
49. Xu Q., Liu G., Yuan X., Xu M., Wang H., Ji J., Konda B., Black K. L., Yu J. S., Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009 27 8 1734 1740 2-s2.0-69249149701 10.1002/stem.102
50. Phuphanich S., Wheeler C. J., Rudnick J. D., Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunology, Immunotherapy 2013 62 125 135
51. + tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. Journal of Neuro-Oncology 2011 105 2 149 157 2-s2.0-82955235579 10.1007/s11060-011-0572- y
52. Cobbs C. S., Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Current Opinion in Oncology 2013 25 682 688
53. Dziurzynski K., Chang S. M., Heimberger A. B., Kalejta R. F., Dallas S. R. M., Smit M., Soroceanu L., Cobbs C. S., Consensus on the role of human cytomegalovirus in glioblastoma. Neuro-Oncology 2012 14 3 246 255 2-s2.0-84859557807 10.1093/neuonc/nor227
54. Cobbs C. S., Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis. Herpesviridae 2011 2, article 10
55. Mailliard R. B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C. M., Kapsenberg M. L., Kirkwood J. M., Storkus W. J., Kalinski P., α -type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Research 2004 64 17 5934 5937 2-s2.0-4344596051 10.1158/0008-5472.CAN-04-1261
56. Langenkamp A., Messi M., Lanzavecchia A., Sallusto F., Kinetics of dendritic cell activation: impact on priming of TH1,TH2 and nonpolarized T cells. Nature Immunology 2000 1 4 311 316 2-s2.0-0034305809
57. Rissoan M.-C., Soumelis V., Kadowaki N., Grouard G., Briere F., De Waal Malefyt R., Liu Y.-J., Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999 283 5405 1183 1186 2-s2.0-0033582629 10.1126/science.283.5405.1183
58. Kalinski P., Smits H. H., Schuitemaker J. H. N., Vieira P. L., Van Eijk M., De Jong E. C., Wierenga E. A., Kapsenberg M. L., IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. Journal of Immunology 2000 165 4 1877 1881 2-s2.0-0034663999
59. Hochrein H., O'Keeffe M., Luft T., Vandenabeele S., Grumont R. J., Maraskovsky E., Shortman K., Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. Journal of Experimental Medicine 2000 192 6 823 833 2-s2.0-0033802387 10.1084/jem.192.6.823
60. Eguchi J., Kuwashima N., Hatano M., Nishimura F., Dusak J. E., Storkus W. J., Okada H., IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. Journal of Immunology 2005 174 11 7194 7201 2-s2.0-18944375915
61. Okada H., Lieberman F. S., Walter K. A., Lunsford L. D., Kondziolka D. S., Bejjani G. K., Hamilton R. L., Torres-Trejo A., Kalinski P., Cai Q., Mabold J. L., Edington H. D., Butterfield L. H., Whiteside T. L., Potter D. M., Schold S. C. Jr., Pollack I. F., Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. Journal of Translational Medicine 2007 5, article 67 2-s2.0-40149090821 10.1186/1479-5876-5-67
62. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T. E., Mintz A. H., Engh J. A., Bartlett D. L., Brown C. K., Zeh H., Holtzman M. P., Reinhart T. A., Whiteside T. L., Butterfield L. H., Hamilton R. L., Potter D. M., Pollack I. F., Salazar A. M., Lieberman F. S., Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α -type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Journal of Clinical Oncology 2011 29 3 330 336 2-s2.0-79951978155 10.1200/JCO.2010.30.7744
63. Salazar A. M., Levy H. B., Ondra S., Kende M., Scherokman B., Brown D., Mena H., Martin N., Schwab K., Donovan D., Dougherty D., Pulliam M., Ippolito M., Graves M., Brown H., Ommaya A., Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996 38 6 1096 1104 2-s2.0-9344238245 10.1097/00006123-199606000-00006
64. Butowski N., Chang S. M., Junck L., DeAngelis L. M., Abrey L., Fink K., Cloughesy T., Lamborn K. R., Salazar A. M., Prados M. D., A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of Neuro-Oncology 2009 91 2 175 182 2-s2.0-57349153494 10.1007/s11060-008-9693-3
65. Zhu X., Nishimura F., Sasaki K., Fujita M., Dusak J. E., Eguchi J., Fellows-Mayle W., Storkus W. J., Walker P. R., Salazar A. M., Okada H., Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of Translational Medicine 2007 5, article 10 2-s2.0-33847674371 10.1186/1479-5876-5-10
66. McNulty S., Colaco C. A., Blandford L. E., Bailey C. R., Baschieri S., Todryk S., Heat-shock proteins as dendritic cell-targeting vaccines-getting warmer. Immunology 2013 139 407 415
67. Crane C. A., Han S. J., Ahn B., Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clinical Cancer Research 2013 19 205 214
68. Smith B. D., Kasamon Y. L., Kowalski J., Gocke C., Murphy K., Miller C. B., Garrett-Mayer E., Tsai H.-L., Qin L., Chia C., Biedrzycki B., Harding T. C., Tu G. H., Jones R., Hege K., Levitsky H. I., K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clinical Cancer Research 2010 16 1 338 347 2-s2.0-75149121612 10.1158/1078-0432.CCR-09-2046